Docetaxel Injection, Solution
Product Images NDC 47335-323

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 47335-323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-docetaxel-160mg-carton (Spl Docetaxel 160mg Carton)

Packaging label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) intravenous solution by Sun Pharmaceutical Industries, Inc. The label states it is ready to add to infusion solution, contains 8 mL, and is for intravenous infusion only. It includes storage instructions, handling warnings, and distributor and manufacturer information.*

FDA Label Image

Spl-docetaxel-160mg-label (Spl Docetaxel 160mg Label)

Label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) solution for intravenous use. Distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ, and manufactured by Sun Pharmaceutical Industries Ltd., Gujarat, India. The label includes storage instructions, dosage details, and a barcode. It specifies the product as a cytotoxic agent with directions for preparation and use.*

FDA Label Image

Spl-docetaxel-20mg-carton (Spl Docetaxel 20mg Carton)

Docetaxel Injection, USP 20 mg/mL is an intravenous injection solution ready to add to infusion solution. The label shows a single-dose vial containing 1 mL, provided by Sun Pharmaceutical Industries, Inc. It includes directions for use, storage instructions, warnings, and manufacturing credits to Sun Pharmaceutical Industries Ltd. in India.*

FDA Label Image

Spl-docetaxel-20mg-label (Spl Docetaxel 20mg Label)

Label for Docetaxel Injection, USP 20 mg/mL intravenous solution. Each mL contains 20 mg docetaxel anhydrous with 4 mg citric acid anhydrous in a 50/50 polysorbate 80 and dehydrated alcohol mixture. The single-dose vial is for intravenous infusion only, distributed by Sun Pharmaceutical Industries, Inc., and manufactured by Sun Pharmaceutical Ind. Ltd., India. Storage is 20 to 25°C, protect from light.*

FDA Label Image

Spl-docetaxel-80mg-carton (Spl Docetaxel 80mg Carton)

The packaging label for Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) solution for intravenous infusion, manufactured by Sun Pharmaceutical Industries, Inc. The label shows the NDC 47335-895-40 and indicates the product is ready to add to infusion solution. The label includes dosage form details, storage instructions, manufacturer and distributor information, and a barcode.*

FDA Label Image

Spl-docetaxel-80mg-label (Spl Docetaxel 80mg Label)

Label for Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) intravenous solution. The label includes the NDC 47335-895-40 and details that each mL contains 20 mg docetaxel anhydrous and 4 mg citric acid anhydrous in a polysorbate 80/dehydrated alcohol vehicle. It is intended for single-dose use, stored at 20-25°C, and protected from light. Distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ, and manufactured by Sun Pharmaceutical Ind. Ltd., India. The label includes placeholders for lot number and expiration date.*

FDA Label Image

Spl-docetaxel-chemical-structure (Spl Docetaxel Chemical Structure)

Chemical structure of Docetaxel, depicting its complex molecular arrangement with multiple rings, hydroxyl, methyl, acetyl, and amide functional groups.*

FDA Label Image

Spl-docetaxel-figure1 (Spl Docetaxel Figure1)

A line chart showing Disease-Free Survival (DFS) Probability (%) over time in months, comparing two treatments labeled TAC (solid line) and FAC (dotted line). The DFS probability decreases over approximately 66 months, with TAC showing a higher survival probability than FAC throughout the period.*

FDA Label Image

Spl-docetaxel-figure10 (Spl Docetaxel Figure10)

A Kaplan-Meier survival probability curve comparing two groups, TPF and PF, over a survival time of up to 72 months. The Y-axis represents survival probability in percentage, and the X-axis represents survival time in months. Below the graph, a table lists the number of patients at risk in each group at multiple time points.*

FDA Label Image

Spl-docetaxel-figure2 (Spl Docetaxel Figure2)

A line graph showing survival probability (%) over time in months for two groups, TAC and FAC. The vertical axis represents survival probability from 0 to 100%, and the horizontal axis represents survival time from 0 to 66 months. The TAC group is represented by a solid line, and the FAC group by a dotted line, illustrating their comparative survival trends over the time period.*

FDA Label Image

Spl-docetaxel-figure3 (Spl Docetaxel Figure3)

A survival curve chart comparing overall survival time in months for two groups labeled T75 and BSC. The y-axis shows cumulative probability from 0 to 1, and the x-axis shows survival time from 0 to 21 months. The chart includes a log-rank p-value of 0.010 indicating a statistical comparison between the two groups.*

FDA Label Image

Spl-docetaxel-figure4 (Spl Docetaxel Figure4)

A Kaplan-Meier survival curve chart depicting overall survival probability over time (in months), comparing two groups labeled T75 (solid line) and V/I (dashed line). The y-axis shows cumulative probability, and the x-axis shows survival time from 0 to 21 months. A log-rank p-value of 0.13 is also noted on the chart.*

FDA Label Image

Spl-docetaxel-figure5 (Spl Docetaxel Figure5)

A survival probability curve chart showing survival time in months on the x-axis and survival probability on the y-axis. Two curves are displayed: a solid line labeled T75 q3w and a dashed line labeled M q3w, depicting comparative survival probabilities over a period up to 30 months.*

FDA Label Image

Spl-docetaxel-figure6 (Spl Docetaxel Figure6)

A Kaplan-Meier survival curve graph displaying probability (%) on the Y-axis versus time in months on the X-axis for two groups labeled TCF and CF. The graph shows survival probabilities declining over 24 months with TCF having generally higher survival probability compared to CF during this period.*

FDA Label Image

Spl-docetaxel-figure7 (Spl Docetaxel Figure7)

This is a survival probability curve graph showing survival time in months on the x-axis and survival probability in percentage on the y-axis. Two survival curves are represented: one solid line for TCF and one dotted line for CF, illustrating survival probabilities over time up to 36 months.*

FDA Label Image

Spl-docetaxel-figure8 (Spl Docetaxel Figure8)

A Kaplan-Meier survival curve graph showing Progression Free Survival (PFS) probability (%) over time in months (up to 42 months). The graph compares two treatment groups labeled TPF (solid line) and PF (dashed line), illustrating differences in PFS probabilities during the study period.*

FDA Label Image

Spl-docetaxel-figure9 (Spl Docetaxel Figure9)

A survival probability curve chart plotting Survival Probability (%) on the vertical axis against Survival Time (months) on the horizontal axis. The chart compares two groups labeled TPF and PF with two lines: a solid line for TPF and a dotted line for PF, showing survival probabilities decreasing over time up to 72 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.